Interdialytic hemodialysis catheter-locking solutions could contribute to a reduction of catheter-related complications, especially infections. However, they can cause side effects because of leakage from the tip of the catheter. Recently, trisodium citrate (TSC) has been advocated because of its antimicrobial properties and local anticoagulation. In a multicenter, doubleblind, randomized, controlled trial, TSC 30% was compared with unfractionated heparin 5000 U/ml for prevention of catheter-related infections, thrombosis, and bleeding complications. The study was stopped prematurely because of a difference in catheter-related bacteremia (CRB; P < 0.01). Of 363 eligible patients, 291 could be randomized. The study included 98 tunneled cuffed catheters and 193 untunneled. There were no significant differences in patient and catheter characteristics on inclusion. In the heparin group, 46% of catheters had to be removed because of any complication compared with 28% in the TSC group (P ‫؍‬ 0.005). CRB rates were 1.1 per 1000 catheter-days for TSC versus 4.1 in the heparin group (P < 0.001). For tunneled cuffed catheters, the risk reduction for CRB was 87% (P < 0.001) and for untunneled catheters was 64% (P ‫؍‬ 0.05). Fewer patients died from CRB in the TSC group (0 versus 5; P ‫؍‬ 0.028). There were no differences in catheter flow problems and thrombosis (P ‫؍‬ 0.75). No serious adverse events were encountered. Major bleeding episodes were significantly lower in the TSC group (P ‫؍‬ 0.010). TSC 30% improves overall patency rates and reduces catheter-related infections and major bleeding episodes for both tunneled and untunneled hemodialysis catheters. Flow problems are not reduced.
I n 2001, approximately 900 per 1 million population in the United States were treated with hemodialysis for ESRD, and an annual increase of 7.1% is expected until 2010 (1, 2) . For chronic hemodialysis treatment, an arteriovenous fistula or graft is preferred for vascular access. However, in current practice, the use of hemodialysis catheters is substantial. From recent data of the Dialysis Outcomes and Practice Patterns Study, it is recognized that 60% of incident and 17% of prevalent patients in the United States depend on a catheter for vascular access (3) . Such widespread application of catheters exposes patients to an enhanced risk for catheter-related complications such as infection and insufficient dialysis as a result of flow problems (4) . Because of these complications, approximately 50% of all catheters have to be removed and/or re-placed, resulting in substantial patient morbidity as well as consumption of resources (5) .
Hemodialysis catheter-related bacteremia (CRB) is the most serious complication, with an average incidence of 3.4 to 6.5 periods per 1000 catheter-days (5) (6) (7) (8) (9) . Recently, it was estimated from the United States Renal Data System and the Medicare reimbursement data that in the United States, there are 22,000 to 100,000 cases of CRB annually in the hemodialysis population and that the costs probably exceed $500 million (2, 10, 11) .
Catheter-related infections are thought to arise by several different mechanisms. Contamination of the catheter hub and subsequent colonization of catheters by microbes as well as formation of a bacterial biofilm on the external and internal surface are thought to be the major routes for both catheterrelated infections and intraluminal thrombosis (12) (13) (14) . Usually, concentrated heparin is used for catheter locking. However, its efficacy is uncertain, and its use is seldom discussed in guidelines. The recently updated and widely accepted Dialysis Outcome Quality Initiative guidelines of the National Kidney Foundation, for example, do not mention heparin for catheter locking (15) . Also, the safety of heparin locking has never been disputed, although it has been demonstrated that heparin causes unintentional systemic anticoagulation and bleeding episodes (16 -18) .
Antimicrobial locking solutions could be an attractive alternative. It is known from in vitro studies that solutions that contain antibiotics can prevent biofilm formation on foreign surfaces (13) . However, solutions that contain high concentrations of antibiotics cannot be used in clinical practice for prevention because of side effects (19, 20) .
High-concentration trisodium citrate (TSC) has been advocated for hemodialysis catheter locking because it provides local anticoagulation. In contrast to heparin, it exposes a broad antimicrobial and anti-yeast effect (21) . TSC chelates of Ca 2ϩ and Mg 2ϩ by which it may prevent biofilm formation and colonization (22, 23) . Currently, there is limited experience with high concentrations of TSC in clinical practice, and the efficacy and the safety of these solutions for improving catheter outcome have yet to be established (24, 25) .
We conducted a multicenter, double-blind, randomized, controlled trial comparing unfractionated heparin 5000 U/ml with TSC 30% for interdialytic catheter locking. The aim was to determine whether locking with TSC 30% could increase overall catheter patency and reduce catheter-related infections. The secondary aim was to establish the safety and whether a difference in major bleeding episodes could be demonstrated.
Materials and Methods

Selection of Patients
The study was conducted from April 2001 until September 2002 in nine dialysis units from the Netherlands and one from Belgium. Two units were situated in an academic center, seven were in a teaching hospital, and one was a private clinic. In the units, the overall average percentage of patients who relied on a catheter for vascular access was 14%. Patients were eligible for enrollment in the study when they were older than 18 yr, were not admitted to the intensive care ward, and experienced chronic or acute renal failure that required hemodialysis treatment by means of a hemodialysis catheter. Only patients with a newly inserted, well-positioned hemodialysis catheter that was expected to be needed for Ͼ1 wk could be included. Catheters were used for hemodialysis treatment only. The specific type and the diameter used were left to the discretion of the interventional physician. The application of national guidelines for dialysis treatment, which state that a femoral catheter should not be used for Ͼ1 wk, that subclavian catheters should be avoided, and that a tunneled cuffed catheter should be used whenever it is foreseen that a catheter would be needed for Ͼ4 to 6 wk, were recommended.
Exclusion criteria were suspected heparin-induced thrombocytopenia or heparin-induced thrombosis, systemic bacterial infection, localized infection requiring systemic antibiotics, proven or suspected allergy to heparin or TSC, and pregnancy. Hospitalization was defined as admission for non-catheter-related reasons at any time a catheter was in place.
The study protocol was approved by the institutional review board of each of the 10 participating institutions, with adherence to the Declaration of Helsinki. Written informed consent was obtained from all patients before enrollment.
Study Design
Patients were randomly assigned to have both lumens of their catheter locked with either unfractionated sodium heparin 5000 U/ml or TSC 30%. Inclusion and randomization was performed immediately after insertion by means of a computer-generated list of random numbers in blocks of six and stratified according to the dialysis center and to the type of catheter inserted (tunneled cuffed or untunneled). Patients and investigators were unaware of the treatment assignments.
The locking solutions were manufactured from raw base according to standardized pharmaceutical protocols in conjunction with European Pharmacopoeia Guidelines and delivered as 5-ml vials (A.J. Wilhelm, Pharmacist, Department of Pharmacy, VU University Medical Center, Amsterdam, The Netherlands). The solutions were heat-sterilized for 16 min at 121°C, and the pH was controlled between 6.4 and 7.5. There were no external recognizable differences in the solutions except for randomization codes. The randomization codes were kept by the central department of pharmacy; all others involved in the study were blinded.
After the hemodialysis treatment had been completed, each lumen of the catheter was flushed with 10 ml of 0.9% sodium chloride and locked with the locking solution using a volume exactly equivalent to the internal volume of the lumen noted on the catheter. For preventing accidental infusion of the locking solution, the maximum size of the syringes used was 2.5 ml. The syringe had to be filled with the amount of locking solution necessary to lock one lumen of the catheter.
Catheter care protocols were according to national guidelines for hemodialysis treatment and included insertion of catheters under strict asepsis by an experienced operator. In addition, these guidelines included catheter exit-site dressing changes after each treatment and catheter manipulations only to be performed by trained dialysis staff wearing masks and sterile gloves. Use of dry gauze dressings and povidone-iodine ointment at the catheter exit site was recommended. Patients were examined for nasal carriage of Staphylococcus aureus on inclusion, and carriers were treated with intranasal 2% mupirocin ointment for 5 d every month. Hemodialysis treatment was performed according to national guidelines with any form of regional anticoagulation being permitted.
Assessment of Outcome
Overall premature catheter removal was defined as any removal needed for a complication such as infection, thrombosis, and catheter breakdown or leakage and unintentional and accidental removals.
Infection
CRB was defined as fever (temperature Ͼ38°C) or cold chills not during a dialysis treatment and at least one positive blood culture and no other obvious cause of infection. In patients who developed signs of bacteremia without symptoms of an alternative source other than the catheter after careful clinical examination by a physician, at least two blood cultures either from the catheter or from a peripheral vein were taken. Subsequently, antibiotics for suspected CRB were given. When a CRB was established, the catheter could be left in place in case of disappearance of fever and clinical recovery on initiation of antibiotic treatment. In patients who did not improve within 48 h or with recurrent bacteremia within 3 wk after stopping antibiotic treatment and without an alternative source, the catheter had to be removed. In case of recurrent bacteremia, only the first period was counted for the analysis.
Exit-site infection was defined as the development of a purulent exudate or redness around the site not resulting from residual stitches. After culturing, antibiotic treatment was recommended for at least 2 wk. In case of no improvement, the catheter had to be removed. CRB-related admissions, defined as admissions solely caused by a CRB, were counted.
Thrombosis
Thrombosis was defined as a persistent inability to run a blood flow of Ͼ200 ml/min despite positional changes of the patient and/or additional flushing. Thrombosis was treated with instillation of urokinase (5000 to 10,000 IU/ml) in both pools with a volume equivalent to the internal volume of the lumen noted on the catheter. After 15 min, the urokinase was withdrawn and the dialysis was continued. When a blood flow of Ͼ200 ml/min was not achieved after this procedure, 100,000 to 250,000 IU of urokinase could be infused in 3 h during dialysis according to the protocol of Twardowski (26) . In case of total occlusion of the lumen (i.e., no flow when connected to the dialysis machine), 40,000 IU/h urokinase during 3 h could be infused in the lumen of the catheter. When this was not successful, the catheter was removed or exchanged. Patients could be re-randomized. In accordance with national guidelines, the minimal acceptable blood flow was 200 ml/min; the target was 250 ml/min. The target for dialysis efficacy was a single-pool Kt/V of at least 1.2 per treatment and a urea reduction rate of 65%.
Safety, Tolerability, and Bleeding Episodes
All noxious and unintended reactions to the locking solution were recorded. Patients were asked to report symptoms after each catheter lock procedure. Persistent bleeding from the place of insertion after catheter placement was considered to be apparent when the patient had to stay on the dialysis unit longer than 3 h or when an intervention with intravenous coagulation promoters was needed. Major bleeding episodes were defined as a clinical evident bleeding a There were no significant differences (at P Ͻ 0.05) between the two groups in any of the summarized characteristics.
episode that included a decrease of the hemoglobin level of 3.6 g/dl (2.0 mmol/L) or more or when a blood transfusion was needed. In case of mortality, the cause was recorded and analyzed. All infectious and thrombotic complications and all catheter removals and adverse events reported by the local investigators were reevaluated by the study coordinators.
Statistical Analyses
Primary analysis was a Cox regression analysis of catheter survival and CRB from the time of randomization (27) . Calculation of the required sample size was based on the assumption that TSC would reduce the premature catheter removal rate from 40 to 30%. With a two-sided test, an ␣ level of 0.05, and a power of 80%, the analysis required 200 catheters per group. With this number of catheters, the power to find a 25% decrease in premature catheter removals is 90%, assuming a rate of 20 per 1000 catheter-days and a mean catheter survival of 40 d (28) . The analysis of outcomes was performed on an intention-to-treat basis. A three-member data-monitoring committee judged an interim analysis after inclusion of 200 catheters. The study was stopped because a greater than predefined (P Ͻ 0.01) significant reduction of the bacteremia rate was found by Cox regression analysis with a statistical difference of P ϭ 0.009.
The effect of the treatment assignment on catheter survival and bacteremia was determined with stratification according to clinical center and type of catheter and was adjusted for the following prespecified baseline factors: Age, gender, race, years of dialysis, presence or absence of diabetes, malignancy, cardiovascular disease, acute renal failure, hospitalization, use of coumarin, nasal carriage of S. aureus. Kaplan-Meier survival curves were constructed (29) . Well-functioning catheters at the end of the study observation time as well as catheters that were removed because they were not needed anymore because patients had a functional arteriovenous access, renal recovery, transfer to peritoneal dialysis, or transplantation were analyzed as censored values. Secondary outcomes, adverse and bleeding events were analyzed by Cox regressions similar to that used in the primary analysis. In case of concurrent CRB and exit-site infection, they were counted as both. We did not add these infections at any time point. All reported P values are two-sided.
Results
Baseline Characteristics of Patients
Of 363 eligible patients during the study period, 291 could be randomized: 143 to heparin and 148 to TSC. Thirty-nine patients were unable or unwilling to give informed consent, in 19 patients the catheter had already been flushed or locked with heparin before consent could be obtained, four patients were admitted at the intensive care unit at the time of catheter insertion, three patients were excluded because of age, three patients were expected to leave to a nonparticipating hospital within 1 wk, one patient had a contraindication to heparin, in one patient the randomization code was lost, one patient had a catheter inserted with another one left in place, and one patient was considered to need a catheter for Ͻ1 wk after inclusion and was withdrawn before the first locking procedure by the caring physician.
The baseline characteristics of the patients were similar in the two treatment groups (Table 1) . A total of 16,547 catheter-days could be analyzed, 9379 catheter-days in 98 tunneled catheters and 7168 catheter-days in 193 untunneled catheters. Because of the stratification method, the groups did not differ significantly with respect to the number of tunneled and untunneled catheters.
Both tunneled (97 of 98; 99%) and untunneled catheters (146 of 193; 76%) were situated mainly in the jugular position. Subclavian catheters were almost completely absent, and only a limited number of femoral catheters (44 of 291; 15%) were used in this study. A variety of double-lumen silicone and polyurethane tunneled and untunneled catheters were used. Tunneled cuffed catheter types included Ash-split (n ϭ 44), Hemo-Cath (n ϭ 24), Tesio (n ϭ 5; all Medcomp, Medical Components, Inc., Harleysville, PA), and Neostar Circle-C (n ϭ 19; Horizon Medical Products, Manchester, GA). Of all untunneled jugular catheters, 140 consisted of a precurved Duoflow (Medcomp) inserted in the low jugular site. This type is known to have relatively low infection rates compared with other types of jugular catheters (8) .
Catheter Patency Rates
The percentage of catheters that had to be removed prematurely was 61% lower in the TSC-locked catheters compared with the heparin-locked catheters (28 versus 46%; relative risk Figure 1 ). The total number of catheters removed prematurely was reduced from 8.1 to 5.0 per 1000 catheter-days in the TSC group. Patency rates for tunneled catheters were much better with TSC versus heparin (RR 0.38, P ϭ 0.015). However, in the TSC-treated group, the survival rates of untunneled catheters did not significantly differ from heparin group (RR 0.69, P ϭ 0.11). Predictors of premature removal were hospitalization (RR 1.78; 95% CI 1.21 to 2.62; P ϭ 0.006) and having an untunneled uncuffed catheter (RR 3.18; 95% CI 2.04 to 4.94; P Ͻ 0.0001; Table 2 ).
Infectious Complications
A total of 33 episodes of CRB occurred in the patients who were randomized to heparin locking compared with nine patients who were assigned to TSC (P Ͻ 0.001). CRB rates per 1000 catheter-days were reduced from 4.1 in the heparin group to 1.1 for TSC. The RR for CRB was 75% lower in patients with a TSC-locked catheter (95% CI 49 to 88%; P ϭ 0.0002). The only other independent predictors of CRB were age Ͻ65 yr (RR 2.99; 95% CI 1.48 to 6.03; P ϭ 0.002) and male gender (RR 2.24; 95% CI 1.15 to 4.35; P ϭ 0.017). Both patients with a tunneled cuffed catheter (RR 0.13; 95% CI 0.04 to 0.39; P Ͻ 0.001) and patients with an untunneled uncuffed catheter (RR 0.36; 95% CI 0.13 to 1.00; P ϭ 0.05) had lower CRB rates with TSC ( Figure 2 , Table  2 ). There were 32 episodes of exit-site infections in the heparin group versus 11 in the TSC group (P ϭ 0.012). In seven of 42 periods of CRB, a concurrent exit-site infection was apparent, equally divided between the treatment groups. All-cause mortality did not differ significantly, but the number of deaths from CRB was lower in the patients with TSC-locked catheters compared with heparin (0 versus 5 patients; RR 0.96; 95% CI 0.93 to 0.99; P ϭ 0.028). Also, the number of admissions for CRB decreased from 21 to six (P ϭ 0.002).
In 71% of CRB cases, cultures yielded Gram-positive microorganisms, predominantly S. aureus or S. epidermidis; in 10%, it concerned Gram-negative microorganisms. The remaining cultures revealed multiple microorganisms. No yeasts were found. Cultures in exit-site infections revealed similar results.
Thrombotic Complications
Twenty-nine of the 143 catheters assigned to heparin locking had to be removed because of persistent flow problems (3.6 per 1000 catheter-days), and 27 of 148 catheters assigned to TSC had to be removed (3.2 per 1000 catheter-days; RR 0.92; 95% CI 0.54 to 1.55; P ϭ 0.75). The need for locally installed urokinase or systemic urokinase administration was not significantly different in the treatment groups ( Table 2 ). During the period that the catheter was in place, 80 of 143 catheters assigned to heparin did not need thrombolytic treatment of any kind (56%), and 79 of 143 assigned to TSC did not need thrombolytic treatment (53%; Table 2 ). Having an untunneled catheter was the only independent risk factor for premature removal because of flow problems (adjusted RR 6.82; 95% CI 3.05 to 15.25; P Ͻ 0.001). Excluding patients with a femoral catheter provided similar results for tunneled and untunneled catheters.
Safety, Adverse Events, and Bleeding Episodes
A total number of 12,624 locking procedures were registered ( Table 3) . No serious adverse events that could be contributed to the locking solution were reported in both groups. Eighteen patients in the heparin group and 13 patients in the TSC group died while having a catheter in place (P ϭ 0.20; Table 2 ). Nine patients immediately after locking with TSC and four patients after heparin locking reported symptoms, mostly perioral or peripheral paresthesia or a "metallic" taste. Symptoms disappeared within 1 min of instillation and did not return in all patients after reduction of the volume used for locking. Unexplained thrombocytopenia was found in four patients on heparin and two on TSC. One patient in the heparin group was withdrawn from the study because of persistent prolonged coagulation times and bleeding complications.
Persistent bleeding from the place of insertion immediately after catheter placement was reported in 19 patients in the heparin group compared with six in the TSC group (P ϭ 0.005). During follow-up, 16 patients in the heparin group experienced a major bleeding episode compared with five patients in the TSC group (P ϭ 0.01).
Discussion
The results of this study show that for hemodialysis catheters, an interdialytic lock of TSC 30% is more effective in preventing premature removal than heparin. TSC reduced the risk for CRB by 75% and reduced the number of patients who died from this serious complication of hemodialysis catheter use. The findings were consistent among the subgroups of patients with tunneled and untunneled catheters. Our results are in agreement with a previous observational catheter-lock study that used high concentrations of TSC. differences between TSC and heparin have been published (25, 30) . These studies, however, accounted for only approximately 5000 catheter-days of pooled data and mostly used lower concentrations of TSC. Adding antibiotics to a locking solution can also prevent CRB. However, widespread use cannot be recommended because the addition of antibiotics in solutions for interdialytic locking of catheters can cause severe side effects through leakage from the tip, resulting in continuous systemic levels of the antibiotic, especially aminoglycosides (19, 20) . Taurolidine-containing solutions have shown promising results. Their limited availability and high costs, however, preclude their use in clinical practice so far (31) .
Our study results are likely to be valid because of the random assignment to treatment groups and the use of a double-blind design. In addition, our study included an average hemodialysis population with catheter-related complications similar to that reported in previous studies (5) (6) (7) 9, 32) . Furthermore, we stratified patients for center and type of catheter to rule out the influence of local differences in catheter care.
All patients with suspected bacteremia had at least two sets of blood cultures drawn from their catheter. Peripheral blood cultures through separate venipuncture sites were not routinely performed. However, it is unlikely that we overestimated the amount of CRB because in our definition we considered a CRB only apparent if the patient had cold chills with positive blood cultures and no other obvious cause of infection. This definition is also used in most other catheter studies because it precludes the need for more punctures for the patients and increases the chance to consent to the study protocol (6, 7, 9, 33) .
We could not show a reduction in premature removals because of thrombotic complications; neither was the use of urokinase for catheter flow problems reduced, suggesting that the mechanism of flow problems is not related to intraluminal biofilm formation. Probably, catheter tip construction and fibrin sheath formation on the outside of the catheter are more important in the pathogenesis of flow problems (8, 34, 35) .
Concerning reduction of patency rates, we could show only a trend and no significant difference in untunneled catheters. This is probably explained by the limited number of untunneled catheter-days included in this study and that many more untunneled catheters had to be removed prematurely because of flow problems. This study is the first that clearly demonstrates that locking of a catheter with heparin is an important cause of bleeding complications in hemodialysis patients. This is in agreement with the occasional observations reported in other studies (16, 18) . The probable explanation is that locking catheters with heparin leads to unintentional leakage of heparin from the catheter, resulting in prolonged bleeding times. This makes patients vulnerable to bleeding complications. We demonstrated that TSC 30% can be used safely as catheter-lock solution. Side effects with TSC have been reported only immediately after locking and are not the result of persistent leakage from the tip during the period when the catheter is locked. The symptoms are probably caused by a temporary drop in Ca 2ϩ and Mg 2ϩ . They disappear after 30 to 60 s because of the large buffer of Ca 2ϩ and Mg 2ϩ in whole blood. There is no solid theoretical base to suggest that prolonged use or multiple locking solutions needed in permanent tunneled cuffed catheters will increase the risk more than individual locking procedures. A total of 12,624 locking procedures were registered. No serious adverse events that could be contributed to the locking solution were reported in both groups. Recently, Stas et al. (25) confirmed this finding in a study that compared heparin 5000 IU/ml and TSC 30% for the evaluation of catheter thrombus formation. It is clear that these potent solutions should be used only by authorized and skilled personnel and that the introduction must be accompanied by a thorough protocol (36) . At present, in the majority of Dutch dialysis units, TSC is used for catheter locking with a strict protocol, and no serious adverse events have been reported.
We did not include a cost-effectiveness analysis in this study as TSC is relatively inexpensive. Prepared from raw base, it is approximately 10-fold less expensive than heparin. However, as was already discussed in the introduction, the reduction of expenditures for vascular access will be impressive when catheter-related complications can be prevented.
In conclusion, the use of TSC 30% for catheter locking in hemodialysis can contribute importantly to the reduction of catheter-related complications in hemodialysis patients by prevention of premature catheter removal and catheter-related infections. Probably, even a reduction in bacteremia-related death can be achieved. In addition, bleeding complications from unintentional heparinization can be reduced.
